- CSR Summary Not Yet Available
- NCT02703272
- Primary Citation
- Data Specification Not Yet Available
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameIbrutinibProduct NameIMBRUVICA®Therapeutic AreaCancers and Other NeoplasmsEnrollment72% Female26.4%% White68.1%
Product ClassKinase InhibitorsSponsor Protocol Number54179060LYM3003Data PartnerJohnson & JohnsonCondition StudiedLymphoma, Non-HodgkinMean/Median Age (Years)12.4